One year ago, I wrote a bullish article on Illumina (NASDAQ: ILMN ), which I encourage readers to review as a primer for this piece. ILMN has provided a total return of 25% (including a slight benefit of the GRAIL (Edward Schneider is a managing director of Quan Management LLC. Mr. Schneider has over 30 years of investment experience, including 25 years managing technology funds in both quoted equities and venture capital. Mr. Schneider holds a CFA designation, an MBA from Thunderbird and a BA from Emory Un ...

In June 2024, GRAIL, Inc. (NASDAQ: GRAL ) was spun-off from Illumina, Inc. ( ILMN ), which had initially acquired GRAIL as recently as 2021. After struggling to defend the merger with regulatory agencies in theI'm Construction Manager for one of America's largest retailers by day, and a stock analyst by night (usually early morning). As a self-taught investor, everything I know about investing came from reading books. Mainly Benjamin Graham, Joel Greenblatt, and Tobias Carlisle, but also countless others.. ...

The market bounced back Monday after a rough week last week. We are not out of the woods yet as a huge CPI report looms on Wednesday. That sort of risk event has the power to rock financial markets. Investors looking for stocks to buy should look outside of the crowded names out there. Yes, there are opportunities outside of the Mag 7. One way to uncover these opportunities is by leaning on the Zacks Rank. Stocks with favorable Zacks Ranks have strong earnings trends which could spell profits in the future. ...

MIAMI, Sept. 9, 2024 /PRNewswire/ -- The FDA has granted approval on Illumina's TruSight Oncology Comprehensive Assay, marking a transformative milestone in cancer diagnostics. This innovative in vitro diagnostic (IVD) kit is the first of its kind, offering distributable comprehensive genomic profiling (CGP) with pan-cancer companion diagnostic claims. PreCheck Health Services is excited to introduce this test under the name SolidTumorCheck+, marking the beginning of a new phase in precision oncology and pa ...

SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment today ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL.Today's judgment confirms Illumina's longstanding view that the European Commission exceeded its authority by asserting jurisdiction over this merger. The basis for the 432 million euro fine has now been removed a ...

Core Insights - Illumina, Inc. has received FDA approval for its TruSight Oncology Comprehensive test, which analyzes over 500 genes to enhance the identification of actionable biomarkers for targeted therapies and clinical trials [1][2] - The TSO Comprehensive test is also approved as a companion diagnostic (CDx) for identifying patients with specific gene fusions, such as NTRK and RET, that may benefit from targeted treatments [2][4] Group 1: Product Development and Approval - The TSO Comprehensive test is designed to profile solid tumors and has been available in Europe since 2022 [1] - It is FDA-approved to identify adult and pediatric patients with solid tumors positive for NTRK gene fusions, which are rare but can be challenging to detect [2][3] - The test also identifies patients with RET fusion-positive non-small-cell lung cancer (NSCLC) who may benefit from Eli Lilly's RETEVMO [4] Group 2: Market Potential and Industry Trends - The global oncology CDx market was valued at $4.78 billion in 2023 and is projected to grow at a CAGR of 8.7% by 2030, driven by the increasing prevalence of cancer and the adoption of personalized medicine [7] - The need for early cancer detection tests is expected to propel market growth, improving disease management and reducing mortality [7] Group 3: Strategic Partnerships and Future Developments - Illumina's collaborations with Bayer and Eli Lilly are essential for advancing cancer diagnostics and expanding access to precision oncology [6] - The company is developing a pipeline of CDx claims through partnerships, which will enhance the TSO Comprehensive test following regulatory approvals [6] Group 4: Recent Company Performance - Illumina's stock has declined by 17.2% over the past year, while its estimated earnings for 2024 have surged nearly 94% to $3.16 per share [9] - The company has consistently beaten earnings estimates in the past four quarters, with an average surprise of 463.5% [9]

"FDA approval for TruSight Oncology Comprehensive with accompanying companion diagnostics marks an awaited milestone for our oncology customers and community," said Everett Cunningham, chief commercial officer of Illumina. "We are committed to partnering with industry leaders like Bayer and Lilly to advance cancer diagnostics and help broaden access to precision oncology for more patients."A CDx test may identify whether a patient's tumor has a specific gene change or biomarker that can be targeted by a the ...

Investors in Illumina, Inc. (ILMN) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 20, 2024 $75 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean ...

da-kukIntroduction Illumina (NASDAQ:ILMN) has finally rid itself of GRAIL. My last look at the stock followed its 2023 financial report, wherein revenues and gross margins dropped and SG&A expenses climbed. The company also projected "approximately flat" revenues in 2024. This was in the context of a valuation that was rich. My recommendation was "sell," noting that the company's "premium valuation is not justified by its current performance or future prospects." Illumina stock is -1.68% since this upda ...

Core Viewpoint - Illumina, Inc. (NASDAQ:ILMN) shows potential for a bullish trend after a significant decline, with recent price action indicating a possible reversal [3][4] Price Action - ILMN has gained over 11% in the last two weeks, recovering from a low of $86.49 in November 2023 [3] - The stock was trading around $350 in February 2022 and reached a high of $540 in February 2021, followed by a downtrend [3] - A critical level to watch is $140; breaking above this could signal a change in trend from bearish to bullish [3][4] Moving Averages - ILMN is currently above its 30-week exponential moving average (EMA), which is considered a bullish indicator [3] - The 30-week EMA may start to rise if the price continues to move higher, indicating a potential shift in trend [3] Volume Analysis - The volume picture shows multiple black spikes, indicating institutional buying, which is a bullish sign [4] - A significant red volume bar occurred with 60 million shares traded, but the price did not decline much, further supporting a bullish outlook [4] Momentum - The Percentage Price Oscillator (PPO) indicates short-term bullish momentum, while long-term momentum remains bearish at -1.258 [4] - There is potential for long-term momentum to shift to bullish if current trends continue [4] Relative Strength - ILMN has been underperforming the SP 500 index since early 2022, but relative strength has trended higher since mid-June, indicating improved performance [4] Summary - Overall, ILMN has shown signs of recovery after a prolonged decline, with improved price action, institutional buying, and potential changes in momentum and relative strength [4]